Patents by Inventor Robert A. Kastelein

Robert A. Kastelein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF AN ANTI-IL-10 ANTIBODY AND A CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER
    Publication number: 20180161427
    Abstract: The present disclosure describes combination therapies comprising an anti-IL-10 antibody or antigen-binding fragment thereof and a CpG-C type oligonucleotide, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 26, 2016
    Publication date: June 14, 2018
    Applicants: MERCK SHARP & DOHME CORP., DYNAVAX TECHNOLOGIES CORPORATION
    Inventors: Ying YU, Elliot Keith CHARTASH, Svetlana SADEKOVA, Uyen Truong PHAN, Robert A. KASTELEIN, Robert L. COFFMAN, Cristiana GUIDUCCI, Robert S. JANSSEN
  • Methods of modulating cytokine activity; related reagents
    Patent number: 9970944
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • METHODS OF MODULATING CYTOKINE ACTIVITY; RELATED REAGENTS
    Publication number: 20180128837
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Application
    Filed: December 20, 2017
    Publication date: May 10, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS
    Publication number: 20140335094
    Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: July 14, 2014
    Publication date: November 13, 2014
    Inventors: Birgit Oppmann, Rene de Waal Malefyt, Donna M. Rennick, Robert A. Kastelein, Maria T. Wiekowski, Sergio A. Lira, Satwant K. Narula
  • USE OF IL-23 AND IL-17 ANTIAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20140248279
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 4, 2014
    Applicants: Merck Sharp & Dohme Corp., The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Antagonists of IL-23P19 for treatement of atopic dermatitis
    Patent number: 8795666
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: August 5, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
  • MAMMALIAN CYTOKINES; RELATED REAGENTS
    Publication number: 20140170658
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 19, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: JACQUELINE C. TIMANS, STEFAN KARL-HEINZ PFLANZ, ROBERT A. KASTELEIN, J. FERNANDO BAZAN, DONNA RENNICK, RENE DE WAAL MALEFYT, JEANNE CHEUNG
  • USE OF IL-23 ANTAGONISTS FOR TREATMENT OF INFECTION
    Publication number: 20140147442
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Application
    Filed: October 28, 2013
    Publication date: May 29, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • METHODS OF MODULATING CYTOKINE ACTIVITY; RELATED REAGENTS
    Publication number: 20140140954
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.
    Type: Application
    Filed: February 3, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jochen Schmitz, Martin Oft, Robert A. Kastelein, J. Fernando Bazan
  • METHODS FOR MODULATING IL-33 ACTIVITY
    Publication number: 20140105887
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Application
    Filed: August 9, 2013
    Publication date: April 17, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Alissa A. Chackerian, Robert A. Kastelein
  • Binding compounds for IL-27
    Patent number: 8691953
    Abstract: Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: April 8, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jacqueline C. Timans, Stefan Karl-Heinz Pflanz, Robert A. Kastelein, J. Fernando Bazan, Donna Rennick, Rene de Waal Malefyt, Jeanne Cheung
  • MAMMALIAN CYTOKINES; RECEPTORS; RELATED REAGENTS AND METHODS
    Publication number: 20140093875
    Abstract: Nucleic acids encoding mammalian cytokine receptor, e.g., for cytokine IL-B50, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: December 2, 2013
    Publication date: April 3, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Pedro A. Reche-Gallardo, Vassili Soumelis, Yong-Jun Liu, Rene de Waal Malefyt, J. Fernando Bazan, Robert A. Kastelein
  • Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment
    Publication number: 20140065147
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
    Type: Application
    Filed: June 19, 2013
    Publication date: March 6, 2014
    Inventors: ROBERT A. KASTELEIN, TERRILL K. MCCLANAHAN, ERIN MURPHY, JASON R. CHAN
  • USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE
    Publication number: 20130323251
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Application
    Filed: August 6, 2013
    Publication date: December 5, 2013
    Applicants: The Government of the United States of America as represented by the Secretary of the Dep. of H.H.S., Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver, Dror Luger
  • Use of IL-23 antagonists for treatment of infection
    Patent number: 8586035
    Abstract: Methods and compositions comprising antagonists of IL-23 are provided for the treatment of infections, such as chronic bacterial, viral and fungal infections.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: November 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Manfred Kopf, Luigina Romani, Robert A. Kastelein, Alissa A. Chackerian
  • COMBINATION THERAPY FOR TREATMENT OF IMMUNE DISORDERS
    Publication number: 20130287775
    Abstract: Methods and compositions are provided for the treatment of immune disorders, such as autoimmune diseases, or cancers, involving combination therapy with agents that inhibit the development or maintenance of Th17 cells. Treatment regimens are provided in which an antagonist of a pro-inflammatory cytokine is administered for a time sufficient to alleviate signs and symptoms of an acute phase flare-up of the autoimmune disease, or cancer, and treatment with an antagonist of IL-23 is continued for a longer time to prevent recurrence of the acute event. Antagonists of PGE2 and CD161 are also disclosed for use in treatment of autoimmune, inflammatory and proliferative disorders.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Edward P. Bowman, Daniel J. Cua, Robert A. Kastelein, Kathy L. Miller, Melanie A. Kleinschek, Kristian S. Bak-Jensen, Katia Boniface, Brent S. McKenzie, Rene de Waal Malefyt
  • Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
    Patent number: 8524230
    Abstract: Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: September 3, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daniel J. Cua, Robert A. Kastelein, Van T. Tsai, Rachel Caspi, Phyllis Silver
  • Mammalian receptor proteins DCRS5; methods of treatment
    Patent number: 8372402
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: February 12, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin Moore, Christi L. Parham
  • USE OF CYTOKINE EXPRESSION TO PREDICT SKIN INFLAMMATION; METHODS OF TREATMENT
    Publication number: 20120276105
    Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.
    Type: Application
    Filed: May 14, 2012
    Publication date: November 1, 2012
    Applicant: Schering Corporation
    Inventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
  • METHODS FOR MODULATING IL-33 ACTIVITY
    Publication number: 20120207752
    Abstract: Provided herein are methods of modulating IL-33 activity, e.g., for the purpose of treating immune diseases and conditions, as well as methods of screening for compounds capable antagonizing IL-33 signaling.
    Type: Application
    Filed: April 25, 2012
    Publication date: August 16, 2012
    Applicant: Schering Corporation
    Inventors: Alissa A. Chackerian, Robert A. Kastelein